| 研究 | 药物 | pCR率 | pCR率 | 参考文献 |
| HR+/HER2+(%) | HR-/HER2+(%) | |||
| WSG-ADAPT | trastuzumabandpertuzumab | NA | 78.6 | [27] |
|
| +/- weekly paclitaxel |
|
|
|
| NeoSphere | Docetaxel | 26 | 63.2 | [25] |
|
| Carboplatin |
|
|
|
|
| Trastuzumab |
|
|
|
|
| Pertuzumab |
|
|
|
| NOAH | Doxorubicin | 30 | 51.2 | [28] |
|
| Paclitaxel |
|
|
|
|
| Cyclophosphamide |
|
|
|
|
| Methotrexate |
|
|
|
|
| Fluorouracil |
|
|
|
|
| Trastuzumab |
|
|
|
| NeoPHOEBE | buparlisib plus trastuzumab | 31.3 | 33.3 | [20] |
|
| and paclitaxel |
|
|
|
| NEOALTTO | Paclitaxel | 41.6 | 61.3 |
|
|
| Lapatinib |
|
|
|
|
| Trastuzumab |
|
|
|
| ADAPT | T-DM1加/或者不加ET | 40 | NA | [21] |
| KRISTINE | 1.trastuzumab emtansine plus | 1. 35·1 | 1. 54·2 | [29] |
|
| pertuzumab 2. Docetaxel, carboplatin + trastuzumab + pertuzumab | 2. 43·8 | 2. 73·2 |
|
| TRYPHAENA (ypT0/is) | 1.FEC + H + P × 3-T + H + P × 3 | 1.46.15 | 1.79.41 | [30] |
|
| 2.FEC × 3-T + H + P × 3 | 2.48.57 | 2.65 |
|
|
| 3.TCH+P×6 | 3.0.5 | 3.83.78 |
|